Breda, the Netherlands / Ghent, Belgium
- Trial met primary endpoint (p ˂0.0001)
- Well-tolerated; safety profile comparable to placebo
- Biologics License Application on track to be submitted to U.S. Food and Drug Administration by end of 2020
- Conference call scheduled for today, May 26, 2020 at 8:30 a.m. EDT (2:30 p.m. CEST)
Attachments
- Original document
- Permalink
Disclaimer
arGEN-X SE published this content on 26 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 June 2020 14:23:40 UTC